Lead: R Brad Jones, Weill Cornell Medicine, USA

R Brad Jones is a viral immunologist and Associate Professor at Weill Cornell Medicine in the Division of Infectious Diseases. His current research is focused on understanding how to effectively harness innate and adaptive cellular immune responses to contribute to the elimination of the HIV reservoirs that persist in individuals on long-term therapy, and thus to inform efforts to cure infection. Work in the Jones lab has led to the discovery of cell-intrinsic resistance to cytotoxic T-cells as a contributor to HIV persistence on long-term antiretroviral therapy, with ongoing research focused on uncovering and overcoming underlying mechanisms. Dr Jones received his PhD in immunology from the University of Toronto before beginning a postdoctoral fellowship at the Ragon Institute of MGH, MIT, and Harvard in 2012. He currently serves as a principal investigator of the NIH-funded Martin Delaney BELIEVE Collaboratory.

---

Jonathan Li, Brigham and Women’s Hospital and Harvard Medical School, USA

Jonathan Li is an Associate Professor of Medicine at the Brigham and Women’s Hospital and Harvard Medical School. He leads an active clinical and translational laboratory research programme focused on viral persistence, reservoirs and resistance, especially within the fields of HIV and COVID-19. He is the Director of the Harvard/Brigham Virology Specialty Laboratory, the Director of the Harvard University Center for AIDS Research Clinical Core and a member of the NIH COVID-19 Treatment Guidelines Panel. He is the protocol Co-Chair of several AIDS Clinical Trials Group studies and the protocol virologist for the ACTIV-2 Adaptive Platform Treatment Trial for Outpatients with COVID-19. He also serves as the Deputy Editor for the Infectious Disease Society of America (IDSA) journal Open Forum Infectious Diseases and on the Editorial Advisory Board for the Journal of Infectious Diseases.

---

Jori Symons, University of Utrecht, Netherlands

Jori Symons is a senior researcher at the Laboratory of Associate Professors Monique Nijhuis and Annemarie Wensing at the University Medical Centre Utrecht, The Netherlands. In 2021 Jori joined the Nijhuis/Wensing laboratory to investigate HIV pathogenesis in the CNS and to perform CRISPR/Cas9 related HIV cure studies. Furthermore, he researches SARS-CoV-2 tropism.  Jori obtained his PhD from the same institute at the Nijhuis/Wensing laboratory in 2014 investigating HIV co-receptor usage in relation to HIV pathogenesis and cure studies. In 2015, Jori joined the laboratory of Professor Sharon Lewin at the Peter Doherty Institute in Melbourne, Australia to investigate HIV pathogenesis through the site of HIV integration. Additionally, he led a small team in curative studies focused on nanoparticle mediated delivery of latency reversal agents. He obtained several national and international grants for his work.

---

Lenine Julie Phillips Liebenberg, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Lenine Liebenberg is a scientist at CAPRISA in the Mucosal Immunology Laboratory and an honorary Senior Lecturer at the University of KwaZulu-Natal. Lenine’s combined training in medical virology, microbiology, genetics, and immunology direct the scope of her research in understanding immune responses at the human genital mucosa. She has documented methods to improve genital cell isolation from men and women, methods to facilitate genital cellular immune responses in multicentre studies, and has characterised genital and systemic immune factors that facilitate HIV infection, viral shedding and HIV transmission.

---

Nicolas Chomont, University of Montreal, Canada

Nicolas Chomont is an Associate professor in the Department of Microbiology and Immunology at the Université de Montréal – CHUM Research Center. He obtained his PhD in medical virology at Pierre et Marie Curie University in Paris. During his post-doctoral training, he identified subsets of memory CD4 T cells that contribute to the persistence of HIV in infected individuals receiving antiretroviral therapy. Since 2015, at the Université de Montréal, he is overseeing studies to unravel the molecular mechanisms involved in HIV latency and to develop novel therapeutic strategies aimed at reducing the size of HIV reservoirs. His work focuses on the immunological mechanisms that are involved in the persistence of HIV-infected cells, and particularly on the role of T cell proliferation in that process.

---

Rachel Rutishauser, University California San Francisco, USA

---

Walter Jaoko, KAVI Institute of Clinical Research, University of Nairobi, Kenya

Walter Jaoko is a Professor of Medical Microbiology and Tropical Medicine and Director of KAVI-Institute of Clinical Research at the University of Nairobi. He is also an Extraordinary Professor of Medicine at Stellenbosch University at the Centre for Bioethics and Law in the Department of Medicine and Adjunct Assistant Professor at the School of Public Health at the University of Alabama at Birmingham. He trained at the School of Medicine at the University of Nairobi, Liverpool School of Tropical Medicine and Hygiene and Stellenbosch University. He has conducted clinical research in various aspects of infectious diseases transmission, treatment and control for the past 30 years, publishing over 200 articles in peer-reviewed scientific journals. He has a keen interest in health research ethics, and the promotion of ethical standards in health research in developing countries, and serves as a member of Strathmore University IRB, a private university in Nairobi, Kenya.

Lead: Brenda Crabtree Ramirez, Salvador Zubirán National Institute of Health Sciences and Nutrition, Mexico

Brenda Crabtree Ramirez graduated with honours in medicine from the La Salle Mexican School of Medicine in 2000. The Universidad Nacional Autónoma de Mexico (UNAM) endorsed her internal medicine specialization from ABC Medical Center. She is an infectious disease specialist at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and currently a senior researcher at the HIV clinic of the Infectious Diseases Department and Assistant Professor of the UNAM HIV/AIDS programme. She has been part of the National System of Researchers since 2010, a member of the Mexican Association of Infectology and Clinical Microbiology since 2007, President of the HIV Committee of the Asociación Mexicana de Infectología y Microbiología Clínica (AMIMC) for 2015-2017, and an IAS Member since 2007. Brenda was Local Chair of the 10th IAS Conference on HIV Science in Mexico City in 2019. She has participated in Phase II-IV clinical trials with anti-HIV/AIDS and opportunistic infection therapies as principal investigator and sub-investigator.

---

Alexandra Calmy, Geneva University Hospital, Switzerland

---

Claudia Cortes, University of Chile, Chile

Claudia Cortes is an internal medicine physician and infectious diseases specialist. Since 2005, she has been dedicated to HIV and AIDS in patient care and research. Currently, she is an Associate Professor at the University of Chile. She was a member and Chair of the HIV advisory committee of the Chilean Infectious Diseases Society (SOCHINF) and is the former Vice President of SOCHINF. She is a consultant for the Chilean Ministry of Health, worked in the development and update of national clinical guidelines for HIV and AIDS management, and took part in several committees involving HIV prevention, testing and treatment strategies. Since 2020, she serves on  the IAS Governing Council.

---

Francois Venter, Ezintsha, University of the Witwatersrand, South Africa

Willem Daniel Francois Venter, FCP (SA), PhD (Wits), Dip HIV Man (SA), DTM&H (Wits) is based at the University of the Witwatersrand, Johannesburg. He leads multiple antiretroviral treatment optimization studies and has an active interest in public sector access to HIV services. He is working on new first- and second-line antiretroviral options, patient linkage to care interventions and HIV self-testing projects. He has led large PEPFAR-funded HIV programmes in South Africa and has been represented on South African and regional HIV guidelines for over a decade, having done almost all his training within South Africa. He has been involved in several human rights cases involving HIV within the southern African region.

---

Rajesh Gandhi, Harvard University, USA

Rajesh T Gandhi, MD, is Professor of Medicine at Harvard Medical School, and the Director of HIV Clinical Services and Education at Massachusetts General Hospital (MGH). He is the site leader of the MGH AIDS Clinical Research Site in the AIDS Clinical Trials Group (ACTG). He is also the Co-Director of the Harvard University Center for AIDS Research (CFAR). He is a member of the NIH Covid-19 Treatment Guidelines Panel and the Infectious Diseases Society of America (IDSA) Covid-19 Treatment Guidelines Panel. He is also a scientific member of the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents, and the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults. Rajesh is a Deputy Editor of NEJM Journal Watch Infectious Diseases and NEJM Journal Watch HIV/AIDS. He graduated from Harvard Medical School, completed his medical residency and chief residency at Brigham and Women’s Hospital and his infectious diseases fellowship training at Johns Hopkins Hospital.

---

Sandra Wagner Cardoso, Oswaldo Cruz Foundation – Fiocruz, Brazil

Sandra Wagner Cardoso graduated in medicine in 1986. She is an infectious diseases specialist with a broad background in HIV and AIDS care as a clinician. She is currently a researcher and one of the core members of the Clinical Trials Unit of the HIV/AIDS Clinical Research Laboratory of the National Institute of Infectology (INI) of the Oswaldo Cruz Foundation (Fiocruz). She is a permanent teaching member of the clinical research post-graduate programme (lato e stricto senso) of INI/Fiocruz. Sje is a member of the AIDS Clinical Trials Group (ACTG), the HIV Prevention Trials Network (HPTN) and the Caribbean, Central and South America network for HIV epidemiology (CCASAnet).

---

Thanyawee Puthanakit, Chulalongkorn University, Thailand

Thanyawee Puthanakit is Division Chief of Pediatric Infectious Diseases in the Faculty of Medicine at Chulalongkorn University, Thailand. Over the past two decades, she has led several NIH-funded multicentre studies on paediatric and adolescent HIV treatment in Thailand and other Asian countries, including Cambodia and Indonesia. Her research expertise includes prevention of mother-to-child transmission of HIV, optimization of antiretroviral treatment in resource-limited settings, HIV co-morbidities and pre-exposure prophylaxis among adolescents. She has served as a committee member for WHO treatment guidelines, on CIPHER at the International AIDS Society, and on the steering committee of TREATAsia. She has published more than 100 peer-reviewed articles on paediatric HIV.

Lead: Ayesha Kharsany, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa

Ayesha Kharsany is an Associate Professor in Medical Microbiology at the University of KwaZulu-Natal, South Africa. She has a PhD and a Masters in epidemiology from Columbia University, New York, USA, and is a member of The Academy of Science of South Africa. As a senior scientist and epidemiologist at CAPRISA, she has extensive research, professional and leadership experience and plays a leading role in the design, regulatory requirements, operations and analysis of HIV and STI epidemiological studies. She focuses on understanding: the evolving HIV epidemic in South Africa; factors influencing HIV acquisition in young women; monitoring HIV prevalence and incidence in association with the scale up of prevention efforts in real-world, non-trial settings; and the cycle of transmission in generalized hyperendemic HIV epidemic settings that are heterosexually driven. She is a principal investigator on several studies and was a co-investigator on the ground-breaking CAPRISA 004 tenofovir gel trial.

---

Adamson Muula, Kamuzu University of Health Sciences, Malawi

---

Damilola (Lola), Walker, UNICEF, USA

Damilola (Lola) Walker is the team lead for UNICEF’s global portfolio on HIV in adolescence, coordinating UNICEF’s contributions to effective national responses to HIV in adolescents and young people and supporting effective advocacy and strategy-setting within the Joint United Nations Programme on HIV and AIDS.  Lola joined UNICEF from the Office of HIV and AIDS at the US Agency for International Development (USAID), where she was Senior Advisor, Pediatric and Adolescent Care and Treatment. She received Masters-level training in international health from the Johns Hopkins Bloomberg School of Public Health  and has over 15 years of experience in health and development.

---

Darrell Tan, St. Michael’s Hospital and University of Toronto, Canada

Darrell Tan is an infectious diseases physician and clinician-scientist at St. Michael’s Hospital and an Associate Professor of Medicine at the University of Toronto, Canada. After earning his undergraduate degree at McGill University in Montréal, Quebec, he completed medical school and residency training (2007) and a PhD in clinical epidemiology (2012) at the University of Toronto. Darrell has dedicated his career to working on the HIV epidemic because of its profound impact on key historically marginalized communities in Canada and abroad, including sexual and gender minorities and racialized populations. His research programme is focused on optimizing strategies for effective HIV prevention and addressing the overlapping epidemics of HIV and other sexually transmitted infections (STIs). He holds a Tier 2 Canada Research Chair in HIV Prevention and STIs, and has been principal investigator or co-principal investigator in multi-centre clinical trials and cohort studies related to pre- and post-exposure prophylaxis (PrEP and PEP), antiretroviral therapy, herpes simplex virus co-infection, syphilis screening and STI prophylaxis.

---

Jason Ong, Monash University, Australia

Jason is a sexual health physician based at Melbourne Sexual Health Centre and an academic with joint appointments at Monash University, University of Melbourne and the London School of Hygiene and Tropical Medicine. His research focuses on improving access to comprehensive sexual health services to all who need it.

---

Joseph Cox, McGill University, Canada

Joseph Cox, MD, MSc, FRCPC, is a medical specialist in Public Health and Preventive Medicine. Joe recently joined the Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada, as Interim Director of the Sexually Transmitted and Bloodborne Infections Surveillance Division. He is an Associate Professor in the Department of Epidemiology, Biostatistics and  Occupational Health, School of Population and Global Health, McGill University (https://www.mcgill.ca/epi-biostat-occh/joseph-cox) and a clinician scientist, Research Institute – McGill University Health Centre (MUHC) (https://rimuhc.ca/-/joseph-cox).  He has more than 20 years’ experience undertaking biobehavioural surveillance and epidemiological research to understand risks for STBBIs and poor health outcomes, among key populations. Before joining the Centre of Communicable Diseases and Infection Control, he was the physician lead for the Sexually Transmitted and Bloodborne Infections service of the Direction régionale de santé publique, CIUSSS du Centre-Sud-de-l’ile-de-Montréal. He continues his work as a staff physician at the Chronic Viral Illness Service, MUHC and remains active in undergraduate and postgraduate medical education as well as graduate-level teaching in epidemiology and public health.

---

Keri Althoff, Johns Hopkins University, USA

Keri N Althoff, PhD, MPH, is an Associate Professor of Epidemiology in the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health. She is one of two Principal Investigators for the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) project. The NA-ACCORD is a collaboration of more than 20 longitudinal HIV cohorts, which rely on electronic medical record data and data collected via research study visits for analyses from most of the cohorts. She also investigates SARS-CoV-2 seroprevalence, disparities in testing, positivity, and clinical outcomes, and the post-acute sequelae of SARS-CoV-2 infection. She is an expert in epidemiologic methods that address challenges in the use of cohort collaboration study design.

---

Monica Ciupagea, UNODC, Austria

Monica Ciupagea, MD, is an HIV expert focusing on Drug Use and HIV at the United Nations Office on Drugs and Crime (UNODC). A national of Romania, she received her medical degree from the Carol Davila University of Medicine and Pharmacy in Bucharest. Monica has over 20 years of experience in the field of HIV prevention, treatment and care among people who use drugs and in providing support to underserved communities such as prisoners, street children, Roma communities and sex workers.  Monica has contributed to the development of gender-tailored public health initiatives and HIV prevention-related strategies at the local, regional and national level throughout Eastern Europe and Central Asia, as well as in South and South East Asia, focusing on addressing the specific needs of women who use drugs.  During her time at UNODC, Monica has also championed civil society participation in the UN system, including through establishing the UNODC Civil Society Group on Drug Use and HIV, which develops a joint work plan to be implemented in partnership by UNODC and members of civil society. She is also the UNODC focal point for the Global Fund Harm Reduction Working Group.

Lead: Margaret Kisikaw Piyesis, Communities, Alliances & Networks (CAAN), Canada

Margaret Kisikaw Piyesis has been CEO of CAAN since December 2019 and Finance and Research Director of the All Nations Hope Network since October 1999. Margaret has over 30 years of experience responding to HIV, HCV and colonial impacts among Indigenous communities. In her culture, she is regarded as Kisewatisowin Okihcitaskwew (Kind-Hearted Warrior Woman). Margaret is Cree Iskwew (a woman) with direct ties to the Kisikaw Piyesis/Itittakoose Family from George Gordon First Nation and the Desnomie/McLeod Family from Peepeekisis First Nation in Saskatchewan on the land now called Canada. She is a descendant of the Moose Clan and the Bear Clan, living as a traditional medicine practitioner, knowledge keeper and “baby-catching bundle carrier”. She is Waniska (Awakened) to the ways of the ancestors, practicing traditional ways of knowing, healing, seeking pimâtisiwin (life) for all nations through Indigenous practices, language, ceremonies, culture and traditions. She works as a Co-Creator for Kisi Manito (Great Mystery), honouring the ancestors along the way.

---

Dinah de Riquets-Bon, Trans United Europe, Netherlands

---

Dominique Gomis, UNFPA, Senegal

Originally from Senegal and trained as a sociologist, Dominique Gomis is also an expert in programme management with more than 21 years’ experience in areas related to the prevention of STIs and HIV.

Dominique is currently a consultant at the UNFPA Regional Office for West and Central Africa. He worked as a national consultant for several international organizations including UNFPA, UNICEF, WHO, IntraHealth, Population Council, Plan International and Africare.

---

Ines Dourado, Federal University of Bahia, Brazil

Ines Dourado, MD, MPH, PhD, is Professor of Epidemiology at the Federal University of Bahia, Brazil. She holds a master’s degree in public health from the University of Massachusetts and a doctorate in epidemiology from the University of California, Los Angeles. Her main research area is on HIV epidemiology and prevention. She has coordinated several multicity research projects in Brazil among key populations, including men who have sex with men, trans women and female sex workers. Currently, Ines is the Protocol Chair and Salvador site PI for the Unitaid funded PrEP1519, a demonstration cohort study of the effectiveness of PrEP amongst adolescent men who have sex with men and trans women in three Brazilian cities: Salvador, São Paulo and Belo Horizonte. She is the author and co-author of numerous articles in peer review journals, documenting her long-term commitment to the production and dissemination of knowledge, as well as contributing to improving the health and quality of life of people at increased risk of HIV acquisition.

---

Lorraine Sherr, University College London (UCL), United Kingdom

Lorraine Sherr, MBE is Professor of Clinical and Health Psychology and Head of the Health Psychology Unit at University College London, UK. With a wide international research portfolio, she was a founding board member for AIDSImpact, an academic member of the Coalition for children affected by AIDS, steering group member of the global MHPSS collaboration and sat on the WHO Strategic Advisory group for AIDS.  She chaired the WHO Disclosure group, and served on two global learning initiatives on Children and AIDS and Violence Prevention.  She has provided evaluations for USAID, UNICEF, PEPFAR, Save the Children, World Vision.  She is the Editor of three international academic journals (AIDSCare, Psychology Health and Medicine, Vulnerable Children and Youth Studies) and has published widely (over 40 books, over 300 academic journal papers).  She was awarded the Swedish NoaksArk Guldarken award in 2018 and an MBE Honour in the Queen’s new year’s Honour list in 2021.

---

Morten Skovdal, University of Copenhagen, Denmark

Morten Skovdal is an Associate Professor at the Department of Public Health, University of Copenhagen. He is a trained community and applied social psychologist and received his PhD from the London School of Economics and Political Science. His research focuses on the contextual factors and relational processes that shape engagement with HIV treatment and prevention services and promote psychosocial wellbeing and care in the community. Much of his work is with underserved groups in sub-Saharan Africa, drawing on participatory methods to attune HIV interventions to their lived realities. He has worked for numerous international organisations, including Save the Children UK.

---

Nompumelelo (Mpumi) Zungu, Human Sciences Research Council (HSRC),  South Africa

---

Renata Arrington-Sanders, Johns Hopkins University, USA

Renata Sanders is an Associate Professor of adolescent medicine, pediatrics and internal medicine at the Johns Hopkins University School of Medicine. Her expertise includes adolescent sexually transmitted infections and HIV, caring for lesbian, gay, bisexual, trans and questioning young people, and transition to adult care. She has a joint appointment in Infectious Diseases in the Johns Hopkins Bloomberg School of Public Health’s Departments of Epidemiology and Health, Behavior and Society. She currently serves on the IAS Governing Council, IAS Stigma Advisory Board, CIPHER Grant Committee and AIDS 2022 Track D Committee.

Lead: Nittaya Phanuphak, Institute of HIV Research and Innovation, Thailand

Nittaya Phanuphak is Executive Director of the Institute of HIV Research and Innovation in Bangkok, Thailand. She started her career in HIV in 2002 by leading a prevention of mother-to-child transmission operational study, which resulted in Thai guidelines allowing the use of three-drug antiretroviral regimens for pregnant women in 2010. Nittaya has a deep interest in key population-led health services (KPLHS), which empower lay providers, members of key populations, to perform HIV/STI testing and dispense PrEP/PEP, antiretroviral treatment and STI treatment to their peers. She is working towards establishing national accreditation and domestic financing systems for key population lay providers to ensure KPLHS sustainability. Nittaya oversees the key population-led Princess PrEP programme, HPTN 083 and the HIV self-testing and PrEP project for men who have sex with men and transgender women aged 15-19 years in Thailand. Nittaya has served as the Asia Pacific representative on the IAS Governing Council since 2018.

---

Carlos Caceres, Caetano Heredia University, Peru

---

Catherine (Cate) Hankins, McGill University, Canada 

Cate Hankins, MD, PhD, FRCPC, CM, is Senior Fellow, Amsterdam Institute for Global Health and Development, Professor at the School of Population and Global Health, McGill University and Co-Chair of Canada’s COVID-19 Immunity Task Force. Chief Scientific Adviser to UNAIDS (2002-2011), she led its scientific knowledge translation team focused on ensuring ethical and participatory HIV prevention trial conduct, convening mathematical modelling teams, and supporting country implementation of proven biomedical HIV prevention modalities. She was Scientific Chair of six annual African INTEREST conferences on HIV (2015-2020). She chairs EDCTP’s Scientific Advisory Committee and NIH’s HIV Prevention Trials Network Scientific Advisory Group. Honorary Professor at LSHTM, she is an HIV Research Trust trustee and IAS Industry Liaison Forum member.

---

Giten Khwairakpam, TREAT Asia – amfAR, Thailand

Giten is currently the Community and Policy Program Manager at amfAR’s TREAT Asia program in Bangkok, Thailand. He is a member of World Health Organization’s Global Guidelines Development Group on hepatitis B and hepatitis C and a member of the Expert Advisory Group on HCV with the Medicines Patent Pool. He also serves in different technical and expert groups on viral hepatitis in WHO’s regional offices for South-East Asia (SEARO) and the Western Pacific (WPRO). He also advises and acts as member of different technical and access committees of international agencies. He has been working on improving HIV and hepatitis C treatment access and advocating for price reductions in South and South East Asia in partnership with regional and national community networks.  He was also profiled as a Change Maker for hepatitis C by the Economist Intelligence Unit in 2017.

---

Jeffrey Lazarus, Barcelona Institute for Global Health, Spain

Jeffrey Lazarus serves as head of the health systems team at the Barcelona Institute for Global Health (ISGlobal) and a Senior Scholar at CUNY Graduate School of Public Health and Health Policy. He is known for having developed the “Fourth 90” in HIV and AIDS and the micro-elimination approach in viral hepatitis C. He is Vice-Chairman of the board of the EASL International Liver Foundation and Co-Chair of the HIV Outcomes Beyond Viral Suppression Coalition. He is the author of more than 250 publications including the global HIV consensus statement. During the COVID-19 pandemic, he joined The Lancet COVID-19 Commission public health taskforce and has been advising governments, NGOs and WHO.

---

Kimberly Green, PATH, Vietnam

Kimberly Green is PATH’s Director for Primary Health Care, overseeing six teams, including teams working on HIV and TB. She has nearly 30 years’ experience focused on health service delivery innovations and is passionate about advancing healthcare for all through community leadership and task-shifting, self-care tools like HIV pre-exposure prophylaxis and self-testing, and innovative health financing. She holds a Master’s in International Health and Development from The George Washington University in Washington DC and a PhD from the London School of Hygiene and Tropical Medicine. She is Clinical Associate Professor at the University of Washington Department for Global Health.

---

Ruanne Barnabas, University of Washington, USA

Ruanne V Barnabas, MD, DPhil, is a Professor in Global Health and Infectious Diseases at the University of Washington and affiliate at the Fred Hutchinson Cancer Research Center. She is a South African Physician-Epidemiologist. Her research focuses on interventions for HIV and STD treatment and prevention and more recently on COVID-19 prevention. She is particularly interested in novel approaches that increase access to services and has led clinical trials with companion health economic modeling to assess the potential impact of interventions, for example, in the Delivery Optimization for Antiretroviral therapy (DO ART) Study, which evaluates the effectiveness and cost-effectiveness of decentralized, community-based ART initiation compared to clinic-based care.  She also leads work assessing innovative strategies to increase access to care including lottery incentives and home delivery. She is the Protocol Chair of the KEN SHE Study to assess the impact of single-dose HPV vaccination in Kenya. Recently, her work has extended to COVID-19 prevention. The ultimate aim of her work is to identify effective and scaleable HIV, HPV, and infectious disease treatment and prevention strategies to increase access across diverse communities and promote equity in health.

Matthew Weait, University of Oxford, United Kingdom

Matthew Weait, FAcSS, FRSPH, is Professor of Law and Society and Director of the Department for Continuing Education at the University of Oxford, UK. His research, scholarship and advocacy have centred on the impact of criminal law and criminal justice processes on people living with HIV. He has published widely in this area and contributed to policy outputs from UNAIDS, WHO Europe and the Global Commission on HIV and the Law, for which he was a member of the Technical Advisory Group. Matthew is a qualified (non-practising) barrister.

---

Alexander McClelland, Carlton University, Canada

Alexander McClelland, PhD, is an Assistant Professor and settler based on the traditional and unceded territories of the Algonquin people in Ottawa, Canada, at Carleton University’s Institute of Criminology and Criminal Justice. He is living with HIV and is a member of the HIV Justice Network Global Advisory Panel.

---

Gnilane Turpin, Johns Hopkins Bloomberg School of Public Health, USA

Gnilane Turpin is a senior research coordinator based at the Center for Public Health and Human Rights, at the Johns Hopkins Bloomberg School of Public Health.  Gnilane works for the key populations programme focused on HIV research studies in West and Central Africa with a focus on interventions aiming to reduce stigma against key populations, particularly female sex workers and men having sex with men. Gnilane has consistently engaged in work addressing structural risk determinants spending a number of years as a frontline counsellor and outreach worker in violence against women and child assault prevention programme.  Throughout this work, Gnilane has demonstrated a commitment to a career in serving those most disenfranchised in the HIV response.

---

Happy Assan, Tanzania network for people who use drugs (TaNPUD), Tanzania

Happy Assan is an activist currently working with the Tanzania Network for People who use drugs and also supports the women-led organization SALVAGE. Happy has been living HIV since 2003 and advocates for vulnerable groups in Tanzania, especially people who use and inject drugs. Happy began using heroin in 1998 and injecting drugs in 2001 and has since had the opportunity to make presentations at local, national and international meetings and conferences. In 2014, Happy led other users to parliament to advocate for changes to a drug bill in Tanzania. They were able to amend several punitive laws that were part of this bill. Happy advocates for drug policies that are grounded in the principles of human rights.

---

Lillian Mworeko, International Community of women living with HIV Eastern Africa, Uganda

---

Max Appenroth, GATE – Global Action for Trans Equality, Germany

Max Nicolai Appenroth (they/them) is a Germany-based trans activist, diversity consultant, and in the final year of their PhD at the Institute of Public Health at the Charité Universitätsmedizin Berlin, Germany. Max works as the Research and Community Sexual Health Officer for the international trans organization GATE – Global Action for Trans Equality.

They are an internationally recognized expert on HIV prevention and care in trans and gender diverse communities and they provide support through their expertise to various different research projects and organizations. In the past years,  Max has collaborated in research and consultancies with WHO, UNAIDS, other key population networks, local and international health research institutes and pharma companies.

---

Renata Tallarico, UNFPA East and Southern Africa, South Africa

Renata Tallarico holds a PhD from Italy on International and European law with a focus on human rights law, a Master’s degree in International Relations and a certificate in International Health and Women’s Rights from Stanford University. She has more than 12 years’ experience working on sexual and reproductive health and rights. She joined UNFPA in 2009 serving as HIV Prevention officer in the Kingdom of Eswatini. She currently works for UNFPA East and Southern Africa Regional Office as Youth team lead and regional coordinator of a programme implemented in 12 countries focusing on adolescents’ sexual and reproductive health and rights. Prior to joining UNFPA she worked in various positions in academia and civil society organizations in Italy and beyond. Renata is a passionate advocate for the realization of the sexual and reproductive rights of all people with a particular interest in adolescents and young people’s rights. She published various articles on matters related to ages of consent to access to sexual and reproductive health services and technically supported various countries during law reforms processes in favour of the realization of sexual and reproductive health and rights.